ACM
IMRX icon

Alethea Capital Management’s Immuneering IMRX Stock Holding History

Alethea Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.36M Buy
472,935
+450,000
+1,962% +$2.28M 0.98% 4
2026
Q1 		$121K Hold
22,935
– – 0.06% 12
2025
Q4 		$151K Hold
22,935
– – 0.07% 11
2025
Q3 		$161K Hold
22,935
– – 0.1% 31
2025
Q2 		$77.3K Buy
+22,935
New +$39.3K 0.06% 29

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Alethea Capital Management's IMRX Position: Q2 2026 in Review

Alethea Capital Management increased its Immuneering (IMRX) stake by 1,962% in Q2 2026, buying an estimated $2.28M and bringing the position to 472,935 shares worth $2.36M. The position accounts for 0.98% of the portfolio, ranked #4.

Alethea Capital Management first reported a position in IMRX in Q2 2025 and has held it in 5 quarters since. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Alethea Capital Management held 472,935 shares of Immuneering worth $2.36M as of Q2 2026.
  • Alethea Capital Management bought 450,000 Immuneering shares in Q2 2026, an estimated $2.28M.
  • Immuneering made up 0.98% of Alethea Capital Management's portfolio in Q2 2026, its #4 holding.
  • Alethea Capital Management first reported a position in Immuneering in Q2 2025 and has held it in 5 quarters since.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Alethea Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.